Observational studyRevista medica del Instituto Mexicano del Seguro Social2023
[Cost-effectiveness of treatment of type 2 diabetes mellitus in México].
Observational study in Revista medica del Instituto Mexicano del Seguro Social, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 5 citations in OpenAlex.
- [Association between anthropometric clinical predictors and HOMA-IR].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Functional Yogurt Enriched withMolecules (Basel, Switzerland) · 2026Article
- [Impact of the national strategy against obesity and diabetes on the incidence of diabetes in Mexico, 2005-2023].Cadernos de saude publica · 2026Article
- A dynamic microsimulation of health outcomes in Mexico's aging population.The Gerontologist · 2025Article
- Comprehensive study of associated factors with Type 2 Diabetes in Mexico: protocol.Revista medica del Instituto Mexicano del Seguro Social · 2025Observational
- Effectiveness of Physical Exercise on Indicators of Metabolic Syndrome in Adults: A Systematic Review with Meta-Analysis of Clinical Trials.Journal of functional morphology and kinesiology · 2025Review
- Estimation of the Burden of Ischemic Heart Disease in the Tabasco Population, Mexico, 2013-2021.International journal of environmental research and public health · 2025Observational
- Macular edema in retinal fundus images by a computational algorithmRevista medica del Instituto Mexicano del Seguro Social · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 Diabetes Mellitus (DM2) is a public health and socioeconomic problem, generating direct medical costs for its treatment. Objective: To analyze the cost-effectiveness of monotherapy and bitherapy treatments in patients with DM2. Methods: Cost-effectiveness, observational, ambispective, cross-sectional and analytical analysis of files in a first level medical unit. The data in the cost matrix was executed with the Office Excel 2010 program; the most prescribed drug was identified and compared with monotherapy and bitherapy. Results: The annual direct medical costs of the total population were drug cost $118,561.70MN, hospitalization cost $243,756.00MN, consultation cost $327,414.00MN and clinical trial cost $2416.79MN, obtaining an annual total of $692,148.58MN. metformin was the most indicated in monotherapy (88.4%) and as standard therapy it has higher cost-effectiveness compared to glibenclamide. In bitherapy it was metformin/glibenclamide (35.7%) versus the therapeutics of metformin/NPH insulin, metformin/insulin glargine and metformin/dapagliflozin, which had a better cost-effective result, with an incremental cost effectiveness of -$1,128,428.50MN, -$34,365.00 MN, -$119,848.97MN respectively. Conclusions: Metformin presented a better cost-effectiveness ratio in monotherapy, while in bitherapy it was the metformin/NPH insulin association.
Indexed as
Identifiers
37201213PMC10396055W4377093067What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.